59413-52-4

Usage

Chemical Structure

Derived from naphthoquinone

Physical State

Colorless solid

Uses

a. Precursor in the synthesis of pharmaceuticals
b. Intermediate in the production of dyes and pigments

Biological Activity

a. Antioxidant properties
b. Anti-inflammatory properties

Potential Applications

a. Treatment of various diseases
b. Cancer treatment
c. Neurodegenerative disorders treatment

Research Status

Further research needed to fully understand its mechanisms of action and potential therapeutic applications.

Upstream product

• 2816-25-3 tricyclo[6.2.2.0(2,7)]dodeca-4,9-diene-3,6-dione 
• 10035-10-6 hydrogen bromide 
• 64-19-7 acetic acid 
• 106-51-4 p-benzoquinone 
• 1165952-91-9 cyclohexa-1,3-diene 
• 2816-25-3 endo-tricyclo[6.2.2.0^2,7]dodeca-4,9-diene-3,6-dione 

Downstream Products

• 1560643-83-5 C₃₁H₃₄F₃N₃O₅S 
• 1560643-87-9 C₄₆H₅₄N₆O₄ 
• 1560640-49-4 C₅₀H₆₀N₈O₆ 
• 1560643-90-4 C₃₆H₄₆BN₃O₄ 
• 1560643-92-6 C₄₂H₅₂N₆O₄ 
• 1560639-95-3 C₄₆H₅₈N₈O₆ 

Relevant academic research and scientific papers

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof, which can also be used for treating HCV infection or a HCV disorder.

Diels-Alder Reactions of 5,8-Ethano-5,8-dihydro-1,4-naphthoquinone with Cyclic Dienes

Diels-Alder cycloadditions of 1,3-cyclohexadiene and cyclopentadiene to ?-facially dissymmetric 5,8-ethano-5,8-dihydro-1,4-naphthoquinone (1) were examined.The stereochemical outcome of the reactions, determined by a combination of chemical and spectral methods, indicates that addition of cyclic dienes to 1 occurs preferentially at the face syn to the etheno-bridge of 1.Cycloadducts 7a/7b and 8a/8b obtained from Diels-Alder reactions of 1 with cyclopentadiene and 1,3-cyclohexadiene undergo -photocyclization to give caged compounds 9a/9b and 10a/10b, respectively.Stereoselective reduction of the enedione double bond in 7a/7b and 8a/8b with aqueous TiCl3 in acetone affords cis-bis-bicyclic ring-fused 1,4-cyclo- hexadiones 11a/11b, and 12a/12b, respectively. - Key Words Polycyclic compounds; Dihydroethano-1,4-naphthoquinone; Diels-Alder reaction; ?-Facial selectivity; 1,4-Cyclohexadiones